Media headlines about DelMar Pharmaceuticals (NASDAQ:DMPI) have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. DelMar Pharmaceuticals earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.2768004644582 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Separately, HC Wainwright set a $12.00 price objective on shares of DelMar Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, November 29th.

Shares of DelMar Pharmaceuticals (DMPI) opened at $1.54 on Wednesday. DelMar Pharmaceuticals has a fifty-two week low of $0.78 and a fifty-two week high of $5.39. The firm has a market cap of $34.13, a price-to-earnings ratio of -2.26 and a beta of 1,227.20.

DelMar Pharmaceuticals (NASDAQ:DMPI) last announced its quarterly earnings data on Monday, November 13th. The company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.01). research analysts forecast that DelMar Pharmaceuticals will post -0.54 EPS for the current year.

In related news, CEO Saiid Zarrabian purchased 60,900 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The shares were purchased at an average cost of $0.82 per share, for a total transaction of $49,938.00. The purchase was disclosed in a document filed with the SEC, which is available through this link.

COPYRIGHT VIOLATION WARNING: This story was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/01/10/delmar-pharmaceuticals-dmpi-receives-media-sentiment-rating-of-0-11.html.

About DelMar Pharmaceuticals

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Insider Buying and Selling by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.